Neurogene Inc. (NASDAQ:NGNE - Free Report) - Stock analysts at William Blair cut their Q1 2026 EPS estimates for Neurogene in a research note issued to investors on Tuesday, August 12th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($1.38) per share for the quarter, down from their prior forecast of ($1.36). The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene's Q2 2026 earnings at ($1.30) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.36) EPS and FY2026 earnings at ($5.37) EPS.
Neurogene (NASDAQ:NGNE - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.10.
NGNE has been the subject of several other research reports. BMO Capital Markets reiterated an "outperform" rating and set a $26.00 price target (up previously from $22.00) on shares of Neurogene in a report on Thursday, June 12th. Baird R W downgraded shares of Neurogene from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Robert W. Baird downgraded shares of Neurogene from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $38.00 to $24.00 in a research report on Friday, May 16th. HC Wainwright reduced their price objective on shares of Neurogene from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, Craig Hallum assumed coverage on shares of Neurogene in a research report on Tuesday, June 17th. They set a "buy" rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.17.
Get Our Latest Stock Analysis on Neurogene
Neurogene Price Performance
Shares of NGNE stock traded down $0.37 during trading on Thursday, reaching $20.74. The company's stock had a trading volume of 9,767 shares, compared to its average volume of 229,992. The company has a market capitalization of $296.00 million, a price-to-earnings ratio of -4.79 and a beta of 1.69. The stock's 50-day moving average price is $20.42 and its 200 day moving average price is $17.21. Neurogene has a 1-year low of $6.88 and a 1-year high of $74.49.
Hedge Funds Weigh In On Neurogene
A number of institutional investors have recently bought and sold shares of NGNE. Two Sigma Investments LP purchased a new position in Neurogene during the 4th quarter valued at about $472,000. GAMMA Investing LLC grew its stake in Neurogene by 2,985.1% during the 1st quarter. GAMMA Investing LLC now owns 4,134 shares of the company's stock valued at $48,000 after acquiring an additional 4,000 shares in the last quarter. Vestal Point Capital LP purchased a new position in Neurogene during the 4th quarter valued at about $1,829,000. Mariner LLC purchased a new position in Neurogene during the 4th quarter valued at about $239,000. Finally, Wells Fargo & Company MN grew its stake in Neurogene by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company's stock valued at $124,000 after acquiring an additional 1,397 shares in the last quarter. Hedge funds and other institutional investors own 52.37% of the company's stock.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.